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ABSTRACT
Deleted in colorectal carcinoma (DCC), a netrin-1 dependence receptor, is 
correlated with  cell progression, migration, and adhesion. Evidence indicated that DCC 
was frequently down-regulated in many cancers. However, the association of DCC with 
breast cancer remains uncertain. We conducted a case-control study to investigate the 
impact of three DCC gene variants (rs2229080, rs7504990, and rs4078288) on breast 
cancer susceptibility in Chinese women. This study included 560 breast cancer patients 
and 583 age-matched healthy controls from Northwest China. The three gene variants 
were genotyped via Sequenom MassARRAY. Odds ratios (ORs) and 95% confidence 
intervals (CIs) were utilized to evaluate the associations. We found that individuals 
with the rs2229080 C/G, C/C, and C/G-CC genotypes had a higher breast cancer risk, 
and the minor allele C was associated with increased breast cancer risk in an allele 
model. We observed a significantly decreased breast cancer risk with the rs7504990 
C/T, T/T, and C/T-T/T genotypes, and the minor allele T was protective against breast 
cancer in an allele model. In addition, rs2229080 was associated with the axillary 
lymph node (LN) metastasis status. An age-stratified analysis revealed an association 
between rs2229080 and reduced breast cancer risk among older patients (≥ 49 years). 
Furthermore, the haplotype analysis showed that the Crs2229080Crs7504990Ars4078288 haplotype 
was associated with a decreased breast cancer risk. However, the results indicated a 
lack of association between rs4078288 and breast cancer risk. These findings affirmed 
that rs2229080 and rs7504990 polymorphisms in DCC  might be related with breast 
cancer susceptibility in Chinese women.
INTRODUCTION
Breast cancer (BC) is the most common type 
of tumors in women worldwide, with 1.8 million 
incident cases and 464,000 death cases in 2013 [1]. 
Approximately 5% to 10% of BCs are metastatic at 
diagnosis, and of these, approximately one-fifth of the 
affected patients will survive for 5 years [2]. A previous 
study estimated that the expression of axon guidance 
molecules (AGMs) was dysregulated during BC 
tumorigenesis and tumor progression, suggesting that 
AGMs might act  as tumor suppressors and oncogene 
activators [3]. 
In the nervous system, axon development is guided 
by diffusible chemoattractants produced by axonal target 
cells [4]. Netrins, a family of extracellular proteins, are 
considered critical axon guidance cues for the positioning 
of axonal growth during neural circuit formation and 
various biological processes, including tumorigenesis, 
adhesion, and angiogenesis [5]. Netrin-1 and netrin-4 are 
the most frequently studied members of the netrin family 
[6]. Netrin-1 expression is elevated in human renal clear 
cell carcinomas relative to normal tissues [7]. Netrin-1 
overexpression is considered a poor prognostic factor 
in ovarian malignancies [8]. A complete loss of netrin-1 
causes embryonic death and severe axon guidance defects 
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in mice [9]. Netrin-1 receptors such as DCC and SAX-3 
(Robo) can function individually or in combination with 
other guidance receptors to control axon growth [10]. 
Evidence shows that DCC is widely expressed by neurons 
and is enriched at synapses to promote synaptogenesis 
between mammalian cortical neurons [11]. In addition, 
DCC can induce apoptosis in the absence of its ligand 
netrin-1 [12]. 
Recently researchers are mostly focused on the 
association between rs2229080, rs7504990 and rs4078288 
polymorphisms in DCC and many cancers. Rs2229080 is 
located on human chromosome 18, with a C/G single-
nucleotide variation, which may alter the DCC expression. 
Rs7504990 and rs4078288 are located in the intron region 
and may not directly affect protein function. Rai et al. [13] 
did not confirm rs4078288 and rs7504990 polymorphisms 
as the risk factors for gallbladder cancer, different with 
the results of GWAS. However, to our knowledge, there 
were no studies involved the association between the 
three DCC polymorphisms and BC susceptibility. In this 
case-control study, we aimed to examine the association 
of these three DCC gene polymorphisms (rs2229080, 
rs7504990, and rs4078288) with BC risk in a Northwest 
Chinese population. 
RESULTS
Characteristics of the patients and controls 
The characteristics of the 560 BC cases and 
583 controls are presented in Table 1. The mean ages of 
patients with BC and healthy controls were 49.09 ± 11.02 
and 48.80 ± 8.28 years, respectively. No significant 
differences were noted between BC cases and controls in 
terms of the age distribution (P = 0.612) and menopausal 
status (P = 0.716). However, the body mass index of 
BC patients significantly differed from health controls 
(P = 0.038). Therefore, statistical analysis based on case-
control comparisons was adjusted for BMI.
Association between DCC gene variants and BC 
risk 
All three SNPs of DCC gene were successfully 
genotyped in 560 patients and 583 controls. The genotypes 
and allele frequencies of the DCC rs2229080, rs7504990, 
and rs4078288 variants are shown in Table 2 and Figure 1. 
The genotype distributions of the three SNPs in healthy 
controls exhibited Hardy–Weinberg Equilibrium (HWE) 
(P = 0.07, 0.50, and 0.99 for rs2229080, rs7504990, and 
rs4078288, respectively), indicating that community 
genetic inheritance was balanced in the control samples 
and that these samples could represent the general 
population.
Among all selected DCC polymorphisms, two 
were found to be associated with the risk of BC. For the 
rs2229080 polymorphism, we found that C/G, C/C, and 
C/G-CC genotype carriers had a significantly increased 
risk of developing BC (OR > 1, P < 0.05); the same trend 
was observed for patients with the C allele (P = 0.007). 
For rs7504990, patients with BC were less likely than 
controls to carry the C/T, T/T, and C/T-T/T genotypes 
(32.3% vs. 38.9%, 5.9% vs. 8.2%, and 38.2% vs. 47.2%, 
respectively), and the minor allele T conferred a reduced 
risk to BC in an allele model (OR = 0.74, 95% CI = 0.61–
0.89, P = 0.002). However, the patients and controls did 
not differ significantly with respect to the frequency of 
any rs4704853 genotypes (P > 0.05). We also obtained the 
statistical power of 0.86 and 0.83 for the two significant 
polymorphisms identified, rs2229080 and rs7504990, 
respectively. This showed that our sample size of 1143 
was adequate and the study was sufficiently able to detect 
the true association of these two polymorphisms with BC.
Association between DCC gene variants and 
clinical parameters of patients with BC
To investigate whether DCC variants were associated 
with the clinical features of patients with BC, we further 
analyzed the distributions of DCC variants with respect to 
a series of clinicopathological parameters including tumor 
size; axillary lymph node (LN) metastasis; and estrogen 
receptor (ER), progesterone receptor (PR), human epidermal 
growth factor receptor 2 (HER-2), and Ki67 index statuses. 
As shown in Table 3, rs2229080 was associated with 
LN metastais in patients with BC (P = 0.01). However, 
no significant correlations were detected between the 
rs7504990 or rs4704853 polymorphisms and clinical 
features of patients with BC (data not shown).
Stratified analysis of DCC gene variants and BC 
risk
The results of a stratified analysis are shown in 
Table 4. When the participants were stratified according 
to age, differences in DCC rs7504990 polymorphism 
distribution were not statistically significant. However, 
for DCC rs2229080, the GA + AA genotype was 
significantly expressed lower frequency among 
older participants (age ≥ 49 years) (OR = 0.65, 95% 
CI = 0.46–0.91, P = 0.01). 
Associations between DCC haplotypes  
and BC risk
We then evaluated the relationship between 
haplotypes and BC risk. Compared with the common 
haplotype Grs2229080Crs7504990Ars4078288, the haplotype 
Crs2229080Crs7504990Ars4078288 was associated with a decreased 
BC risk (OR = 0.74, 95% CI = 0.61–0.90, P = 0.003, 
Table 5). We also observed a significant association 
between other haplotypes and BC risk (P < 0.001).
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DISCUSSION
DCC is a single-pass transmembrane protein 
that belongs to the immunoglobulin superfamily, and 
it is a candidate tumor suppressor gene located on 
chromosome 18q21 [14]. DCC extends more than 1.2 Mb 
with 29 exons [15], and is the largest tumor suppressor 
gene identified to date. It is expressed in most normal 
tissues, including the colonic mucosa, and its expression 
was greatly reduced or absent in most tested colorectal 
carcinomas [16]. DCC directs cell invasion through the 
basement membrane, an essential step in the pathological 
progression of human cancer [17]. Currently, DCC 
is known to be involved  in the following biological 
processes: guidance of developing axons,4 induction of 
apoptosis [18], control of colorectal tumorigenesis [19], 
and angiogenesis [20]. DCC alterations are apparent in 
early-stage gastric cancers, emphasizing the importance of 
this growth regulatory pathway in gastric carcinogenesis 
[21]. Significant differences were observed between 
cases without metastasis or local recurrences versus 
those with metastasis or local recurrences, suggesting 
that a decrease in DCC expression might influence the 
prognosis of patients with breast cancer [22]. However, 
no significant role for DCC alterations has been found in 
the pathogenesis of meningiomas [23]. 
In previous studies, DCC gene variants were found 
to be correlated with some types of cancer. Rai et al. 
[13] found that the DCC haplotype G (rs2229080)-A 
(rs4078288)-C (rs7504990)-A (rs714) conferred a 
high risk of gallbladder cancer. The rs714 (A > G) 
polymorphism contributes to the risk of esophageal and 
gastric cancers in a Kashmiri population [24]. To date, the 
possible effects of DCC variants had not been studied in 
BC. In our study, we have provided the initial observation 
that the DCC genotype variants rs2229080 and rs7504990, 
but not rs4078288, contributed differentially to BC 
susceptibility. The haplotype Crs2229080Crs7504990Ars4078288 had 
a significant relationship with decreased BC risk.
A previous study found increased DCC expression but 
a lower rate of axillary lymph node metastasis in mucinous 
carcinoma than in non-mucinous carcinoma in the human 
female breast [25]. DCC-negative, HER-2 overexpressing 
tumors were found to have a marginal influence on the 
survival duration of patients with BC, indicating that 
reduced DCC expression and HER-2 overexpression might 
influence the prognosis of BC [26]. However, that finding 
differs from our results. According to our study, the DCC 
Table 1: Distributions of select variables in breast cancer cases and cancer-free controls
Characteristics Cases Control P value*
Number 560 583
Age (mean ± SD) 49.09 ± 11.02 48.80 ± 8.28 0.612
Menopausal status
Premenopausal 264 281
Postmenopausal 296 302 0.716
Body mass index (kg/m2)
(mean ± SD) 22.52 ± 2.84 22.95 ± 3.21 0.038
Tumor size < 2 cm 188
≥ 2 cm 372








Ki67 < 14% 195
 ≥ 14% 365
*T-test or two-sided χ2-test.
LN:  Axillary lymph node; ER: Estrogen receptor; PR: Progesterone receptor; HER-2: human epidermal growth factor 
receptor 2.
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Table 2: Genotype and allele frequencies of the DCC polymorphisms among the cases and controls 
and the associations with breast cancer risk
Model Genotype Case (560) Control (583) OR (95% CI)† P-value*
rs2229080  HWE = 0.07
Codominant G/G 158 (28.2%) 212 (36.3%) 1.00 (reference)
C/G 313 (55.9%) 296 (50.8%) 1.42 (1.09–1.84) 0.008
CC 89 (15.9%) 75 (12.9%) 1.59(1.10–2.31) 0.013
Dominant GG 158 (28.2%) 212 (36.3%) 1.00 (reference)
C/G-C/C 402 (71.8%) 371 (63.7%) 1.45(1.13–1.87) 0.003
Recessive G/G-C/G 471 (84.1%) 508 (87.1%) 1.00 (reference)
C/C 89 (15.9%) 75 (12.9%) 1.28 (0.92–1.78) 0.144
Allele G 629 (56.2%) 720 (61.7%) 1.00 (reference)
C 491 (43.8%) 446 (38.3%) 1.26(1.07–1.49) 0.007
rs7504990  HWE = 0.50
Codominant C/C 346 (61.8%) 308 (52.8%) 1.00 (reference)
C/T 181 (32.3%) 227 (38.9%) 0.71 (0.55–0.91) 0.007
T/T 33 (5.9%) 48 (8.2%) 0.61 (0.38–0.98) 0.039
Dominant C/C 346 (%) 308 (52.8%) 1.00 (reference)
C/T-T/T 214 (38.2%) 275 (47.2%) 0.69 (0.55–0.88) 0.002
Recessive C/C-C/T 527 (94.1%) 535 (91.8%) 1.00 (reference)
T/T 33 (5.9%) 48 (8.2%) 0.70 (0.44–1.11) 0.123
Allele C 873 (77.9%) 843 (72.3%) 1.00 (reference)
T 247 (22.1%) 323 (27.7%) 0.74 (0.61–0.89) 0.002
rs4078288  HWE = 0.99
Codominant A/A 307 (54.8%) 304 (52.1%) 1.00 (reference)
G/A 212 (37.9%) 234 (40.1%) 0.90 (0.70–1.15) 0.384
G/G 41 (7.3%) 45 (7.7%) 0.90 (0.57–1.42) 0.655
Dominant A/A 307 (54.8%) 304 (52.1%) 1.00 (reference)
G/A-G/G 253 (45.2%) 279 (47.9%) 0.90 (0.71–1.13) 0.364
Recessive A/A-G/A 519 (92.7%) 538 (92.3%) 1.00 (reference)
G/G 41 (7.3%) 45 (7.7%) 0.94 (0.61–1.47) 0.799
Allele A 826 (73.8%) 842 (72.2%) 1.00 (reference)
G 294 (26.2%) 324 (27.8%) 0.93 (0.77–1.11) 0.408
*Two-sided χ2 test for the distributions of genotype and allele frequencies. 
†Adjusted for age and body mass index. 
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rs2229080 polymorphism was associated with the lymph 
node metastasis status. Furthermore, rs2229080 conferred 
a decreased BC risk in older individuals (≥ 49 years). Our 
results demonstrate that the rs2229080 polymorphism 
might play a critical role in BC susceptibility. Moreover, 
DCC rs2229080 polymorphism was reported to occur more 
frequently in stages C and D in colorectal cancer, and may 
serve as a prognostic factor for colorectal cancer patients 
[27]. Rs2229080 polymorphism is located in the coding 
region, which may decrease DCC gene expression. The 
expression of DCC is mostly lost or reduced in later clinical 
stage, higher pathological grade, and poor prognosis in 
ovarian cancer [28].
Our study had some limitations. First, the sample 
size was inadequate for a stratified analysis and for an 
analysis of these associations in patients with mix-type 
BC. As this is the first report of genetic BC susceptibility 
related to DCC polymorphism, similar studies with larger 
sample sizes will be needed for further verification. 
Second, we did not investigate whether predisposing 
factors, including high-dose radiation exposure, alcohol 
consumption, and postmenopausal obesity, were associated 
with the risk of BC because of a lack of such data from 
both BC patients and healthy controls. The effect of these 
factors on BC risk should be assessed in a future study.
In conclusion, our case-control study indicates 
that the rs2229080 and rs7504990 polymorphisms in 
DCC might affect BC susceptibility and progression in 
Chinese women. Further functional studies and large 
population-based prospective studies will be needed to 
provide accurate evidence about the influence of DCC 
variants on BC. 
Figure 1: (A) Genotype frequencies of the DCC polymorphisms among the cases and controls. (B) Allele frequencies of the DCC 




The study was approved by the Institutional 
Review Board of Xi’an Jiaotong University (Xi’an, 
China). Written informed consent was obtained from 
all participants involved in the study at the time of 
recruitment.
Study population
We conducted a hospital-based case-control study 
of 560 BC patients and 583 cancer-free controls. All 
participants were recruited without the restrictions of 
age. All patients met the present pathological criteria of 
sporadic BC and were diagnosed between January 2013 
and October 2014 at the Second Affiliated Hospital of 
Xi’an Jiaotong University, China. Patients who  had 
other types of cancer were excluded from the study. The 
controls were randomly selected from among healthy 
volunteers who underwent annual physical examinations 
in other hospital departments and who had no prior history 
of cancer. Controls were frequency matched to patients 
according to age (±5 years). The methods were performed 
in accordance with the approved guidelines. All research 
participants provided written informed consent and were 
interviewed to obtain detailed information regarding age, 
sex, ethnicity, religion, place of residence, education, and 
other potential confounding factors of interest. After the 
Table 3: The associations between the DCC polymorphisms and clinical characteristics of breast 
cancer patients 
Variables rs2229080 rs7504990
G/G (%) C/G+C/C(%) P * OR (95%CI) CC (%) C/T+T/T (%) P * OR (95%CI)
Tumor size
< 2 cm 54 (28.7%) 134 (71.3%) 1.00 (reference) 127 (67.6%) 61 (32.4%) 1.00 (reference)
≥ 2 cm 104(28.0%)
268
(72.0%) 0.85 1.04 (0.70–1.53) 219 (58.9%) 153 (41.1%) 0.05 1.46 (1.01–2.10)
LN metastasis 
Negative 81 (37.3%) 155 (62.7%) 1.00 (reference) 143 (60.1%) 93 (39.4%) 1.00 (reference)
Positive 77(23.8%)
247

















(72.9%) 1.00 (reference) 155 (60.8%) 100 (39.2%) 1.00 (reference)




(70.4%) 1.00 (reference) 246 (63.2%) 143 (36.8%) 1.00 (reference)




















* Two-sided χ2 test for the distributions of genotype frequencies. 
LN:  Axillary lymph node; ER: Estrogen receptor; PR: Progesterone receptor; HER-2: human epidermal growth factor 
receptor 2.
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interview, approximately 2 mL of venous blood sample 
was collected from each healthy control and breast 
cancer patient before they received the chemotherapy or 
radiotherapy . 
Genotyping assay
Whole blood samples were placed into EDTA-coated 
tubes and preserved at −80°C until further use. Genomic 
DNA was isolated from the whole blood samples using 
a standard phenol-chloroform extraction method. DNA 
concentrations were measured via spectrometry (DU530 
UV/VIS spectrophotometer; Beckman Instruments, 
Fullerton, CA, USA). For our study, we selected candidate 
SNPs in TIM according to HapMap data from a Chinese 
population. To achieve a power of at least 50%, only 
SNPs with a minor allele frequency (MAF) > 0.01 was 
included. Sequenom MassARRAY Assay Design 3.0 
Software (Agena Bioscience, San Diego, CA, USA) 
was used to design a Multiplexed SNP MassEXTEND 
Table 6: Primers used for this study










Table 5: Association between DCC haplotypes and breast cancer risk
Haplotypes Controls
(N = 1166) 
n, %
Cases
(N = 1120) 
n, %
OR
(95% CI) Prs2229080 rs7504990 rs4078288
G C A 416 (35.68%) 348 (31.07%) 1.00 (reference)
G T G 296 (25.39%) 226 (20.18%) 1.10(0.88–1.37) 0.424
C C A 420 (36.02%) 473 (42.23%) 0.74(0.61–0.90) 0.003
C T G 21 (1.80%) 16 (1.43%) 1.10(0.56–2.14) 0.783
Others 13 (1.11%) 57 (5.09%) 0.19(0.10–0.35) < 0.001












P* OR (95% CI)†
N (%) N (%) N (%) N (%)


















































*Two-sided χ2 test for the distributions of genotype frequencies. 
†Adjusted for age and age at menarche.
Oncotarget32772www.impactjournals.com/oncotarget
assay. Finally, three SNPs (rs2229080, rs7504990, and 
rs4078288) were selected according to Chinese population 
data from HapMap. DCC SNP genotyping was performed 
using a Sequenom MassARRAY RS1000, according to the 
manufacturer’s instructions. The corresponding primers 
used for each SNP in this study are listed in Table 6. 
Sequenom Typer 3.0 Software (Sequenom Inc., San 
Diego, CA, USA) was used for data analysis. 
Statistical analyses
The statistical power of the case-control study was 
calculated using QUANTO software 1.2.4 (University of 
Southern California, Los Angeles, CA, USA; http://biostats.
usc.edu/Quanto.html). HWE was tested by chi-square test 
for each SNP before the analysis. The Student t-test or the 
t2 test was used to compare differences in the distributions 
of demographic characteristics, selected variables, and 
genotype frequencies between the cases and controls. 
We conducted a case-control study for all of the subjects, 
and then the patients were stratified by age. Odds ratios 
(ORs) and 95% confidence intervals (CIs) were used to 
assessed the degree of association betweenDCC rs2229080, 
rs7504990, and rs4078288 polymorphisms and BC. Allele 
and genotype frequencies were calculated and compared 
between patients and controls using SPSS 18.0 for Windows 
(PASW Statistics; SPSS Inc., Chicago, IL, USA). Haplotype 
analysis was performed with in each gene under the 
generalized linear models by using the software PHASE. 
P values < 0.05 were considered to indicate statistical 
significance, and all statistical tests were two-sided.
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